Table 2.
Patients requiring further imaging to reach a diagnosis and therapy decision after initial imaging (efficacy population)
| No. of patients requiring further imaging | Test result |
||
|---|---|---|---|
| P‡ | Rate difference (%)† | ||
| Gadoxetic acid-enhanced MRI | 0 of 118 (0) | ||
| ECCM-MRI | 19 of 112 (17·0) | < 0·001 (H03) | 17·0 (11·4, 25·6) |
| CE-CT | 44 of 112 (39·3) | < 0·001 (H02) | 39·3 (30·7, 49·8) |
| Pooled ECCM-MRI–CE-CT | 63 of 224 (28·1) | < 0·001 (H01) | 28·1 (22·5, 34·6) |
Values in parentheses are
*
percentages and
†
95 per cent repeated confidence intervals of the rate differences between gadoxetic acid-enhanced magnetic resonance imaging (MRI) and each of the comparators below, corresponding to the hierarchically ordered null hypotheses H01, H02, H03 (H0i:rategadoxetic acid-enhanced MRI ≤ ratecomparator(i) with i = 1,2,3)23,24. ECCM, extracellular contrast medium; CE-CT, contrast-enhanced computed tomography.
‡
One-sided Fisher's combination test of the entire population.